Chemours Q4 revenue falls

The Chemours

19/02/2026 21:47

Overview

Chemicals firm's Q4 revenue fell 2% yr/yr, driven by volume declines

Adjusted EBITDA for Q4 decreased 24% yr/yr

Outlook

Company projects full-year 2026 net sales growth of 3 to 5%

Chemours anticipates full-year 2026 adjusted EBITDA between $800 mln and $900 mln

Result Drivers

TSS GROWTH - Record Q4 performance in TSS driven by 37% growth in Opteon™ Refrigerants

TT DECLINE - TT segment sales decreased due to lower TiO2 pigment pricing and volume, especially in non-western markets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
Meet
$5.80 bln
$5.80 bln (9 Analysts)
FY Adjusted EPS
Miss
$0.95
$0.96 (9 Analysts)
FY Adjusted Net Income
Miss
$143 mln
$145.74 mln (9 Analysts)
FY Adjusted EBITDA
Miss
$742 mln
$755.21 mln (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the diversified chemicals peer group is "buy."

Wall Street's median 12-month price target for Chemours Co is $15.00, about 29.1% below its February 18 closing price of $21.15

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release: ID:nPnQ3zrFa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)